Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Large Blend · Lord Abbett

Lord Abbett Fundamental Equity Fund Class R3 (LAVRX)

Ticker LAVRX · · Holdings as of Jul 31, 2026

Expense ratio
1.18%$118/yr per $10k
5-yr return
+13.0%annualized
1-yr return
+16.9%as of Dec 2025
Net assets
$2.2Ball share classes
Holdings
57

Bottom line

Is LAVRX a good fund? The bottom line

LAVRX is the Class R3 share class of Lord Abbett Fundamental Equity Fund, a managed large blend mutual fund from Lord Abbett.

It charges 1.18% — about $118 a year on every $10,000 invested, more expensive than 73% of large blend funds we track.

It returned +16.9% over one year, +13.0% a year over five years, +10.6% a year over ten (as of Dec 31, 2025, per its prospectus).

With $2.2 billion in net assets and 57 holdings, its largest position is Alphabet Inc (4.5%) and the top 10 make up 28.1% of the portfolio.

What stands out

  • 5-year return beat 75% of category peers
  • No front-end sales load

What to watch

  • Expensive for its category (1.18%)
  • 12b-1 marketing fee of 0.5% a year

Updated Nov 19, 2026

What LAVRX invests in

The Funds investment objective is long-term growth of capital and income without excessive fluctuations in market value.

The Fund invests in equity securities of U.S. and multinational companies across all market capitalization ranges that the portfolio management team believes are undervalued by the market and are selling at reasonable prices in relation to the portfolio management teams assessment of their potential or intrinsic value. Under normal conditions, the Fund invests at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in equity securities. The Fund normally invests at least 50% of its net assets in equity securities of large, established companies having a market capitalization within the range of companies in the Russell 1000 Index. The Fund seeks to invest in securities of companies that the portfolio management team believes are undervalued by the market and are selling at reasonable prices in relation to the portfolio management teams assessment of…

From the fund's prospectus (filed Feb 25, 2026).

LAVRX performance

Average annual total returns
1 yr5 yr10 yr
LAVRX+16.9%+13.0%+10.6%
Large Blend median+13.8%+9.7%+10.9%

Source: Fund prospectus, as of Dec 31, 2025

Full LAVRX performance history →

What LAVRX costs

On a $10,000 investment, LAVRX's 1.18% expense ratio costs about $118 a year. The prospectus estimates $1,432 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.

See the full LAVRX fee table →

LAVRX top 10 holdings

#Holding% of fund
1Alphabet Inc4.52%
2JPMorgan Chase & Co4.05%
3Microsoft Corp2.90%
4Taiwan Semiconductor Manufacturing Co Ltd2.58%
5UnitedHealth Group Inc2.52%
6RTX Corp2.42%
7Wells Fargo & Co2.40%
8Shell PLC2.38%
9SEI Investments Co2.20%
10United Therapeutics Corp2.11%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 28.1% of the fund. See all top 25 holdings and asset mix →

Alternatives to LAVRX

More funds like LAVRX →

LAVRX FAQ

What is the expense ratio of LAVRX?
LAVRX's expense ratio is 1.18%, which works out to about $118 a year for every $10,000 invested. The prospectus estimates total costs of $1,432 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is LAVRX a good investment?
It depends on your goals, but the data points to: 5-year return beat 75% of category peers; no front-end sales load; expensive for its category (1.18%); 12b-1 marketing fee of 0.5% a year. This is general information, not personalized advice.
What does LAVRX hold?
LAVRX's largest holdings are Alphabet Inc (4.5%), JPMorgan Chase & Co (4.0%), Microsoft Corp (2.9%), Taiwan Semiconductor Manufacturing Co Ltd (2.6%), UnitedHealth Group Inc (2.5%). It holds 57 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is LAVRX's 5-year return?
LAVRX returned +13.0% a year over the five years ending Dec 31, 2025, and +10.6% a year over ten years. Past performance does not guarantee future results.
Does LAVRX have a sales load?
No. LAVRX has no front-end sales charge.
Who manages LAVRX?
LAVRX is offered by Lord Abbett through Lord Abbett Securities Trust.